I ODINE-induced hyperthyroidism has been observed in patients with euthyroid nodular goiter, patients with subclinical Graves' disease, and subjects without any apparent thyroid disease (1, 2). In the patients with subclinical Graves' disease, iodine administration and an increase in dietary iodine intake have been reported to induce and exacerbate the hyperthyroidism (l-3). Furthermore, it has been suggested that increased dietary iodine intake is associated with an increased recurrence rate of hyperthyroidism in patients previously treated with antithyroid drugs for Graves' disease (4, 5).
In euthyroid patients previously treated with 1311 and partial thyroidectomy for Graves' disease, iodine administration may induce hypothyroidism (6). Studies on the effects of iodine administration in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism have yielded conflicting results (7, 8) . In the present study, we have evaluated the effects of pharmacological amounts of iodine on thyroid function in euthyroid subjects previously treated with methimazole (MMI) for hyperthyroid Graves' disease. Levels of serum AbTPO and TSH-RAb higher than 100 U/ mL and 15 U/L, respectively, were considered to be positive. Urinary iodine excretion was measured in a morning urine sample by the method of Benotti et al. (9) , and values of iodine excretion were calculated as micrograms per g creatinine. I-ClO, discharge tests were carried out in 8 euthyroid women, aged 30.5 + 2.2 yr, who had never had autoimmune thyroid disease (10). All had a negative I-Cl04 discharge test. TRH tests were carried out in 4 of these women who were then given SSKI and studied over the same period of time as the 10 EG subjects.
Basal serum TSH concentrations in the EG subjects before SSKI administration were considered elevated when they exceeded the mean + 2 SD of values in the control subjects. During SSKI administration, the EG patients were considered to have elevated serum TSH concentrations when one or more serum TSH values were higher than the highest mean + 2 SD of TSH concentrations in the control subjects during SSKI administration.
TRH-stimulated serum TSH concentrations in EG subjects were considered elevated when they were higher than the corresponding mean + 2 SD of values in control subjects (11 
Results
Thyroid status before SSKZ administration (baseline) Serum Til, T3, and basal and TRH-stimulated TSH concentrations in the EG subjects were similar to those observed in control subjects (Table 1) . Furthermore, none of the EG subjects had elevated or suppressed serum TSH responses to TRH.
I-ClO, discharge tests were positive in 4 of the 10 EG subjects and in none of the 8 control subjects (P < 0.01, by Fisher's exact test).
Serum AbTPO levels were elevated in seven EG subjects, four of whom had positive I-ClO, discharge tests. The mean AbTPO level was 3954 f 2222 U/ml. Serum TSH-RAb were not detected in any of the Eg subjects. AbTPO and TSHRAb were undetectable in the control subjects.
Urinary iodine excretion in the 14 women averaged 162 PLg iodine/g creatinine.
Thyroid status during SSKZ administration
During SSKI administration, there was no significant change in serum TSH concentrations in the control subjects; the highest value was observed on day 60 (mean f SD, 3.5 + 2.5 mu/L). On day 90 of SSKI administration, the control women had a mean serum TSH response to TRH of 21.8 f 10.9 mU/L (mean + SD), a value significantly higher than that observed before SSKI administration (P < 0.01, by Student's t test). Based on the values observed in the normal women, basal and TRH-stimulated serum TSH values higher than 8.5 and 43.6 mu/L, respectively, were considered to be elevated. Serum T4 and T3 concentrations did not change in the control subjects during SSKI administration.
During SSKI administration, one EC subject had serum TSH concentrations of 10.6 and 15.9 mU/L on days 30 and 60, respectively, and another had a TSH response to TRH on day 90 of 50.1 mU/L (Table 2) . Thus, these 2 EG patients with elevated basal or TRH-stimulated serum TSH concentrations were considered to have iodine-induced subclinical hypothyroidism, since serum T4 and T3 concentrations during SSKI administration fluctuated within the normal range, and signs of hypothyroidism were not observed (Table 2) . Both patients had elevated serum AbTPO concentrations before and during SSKI administration, and one had a positive I- C104 discharge test. The other eight EG subjects had a slight increase in basal serum TSH concentrations during SSKI administration, reaching the highest value on day 60 (3.9 + 1.4 mu/L; P < 0.01, by 1 way ANOVA). In these eight EG subjects, the TSH response to TRH on day 90 was 21.9 f 4.3 mu/L, significantly higher than that observed before SSKI administration (P < 0.01, by Student's t test), but not different from values in the control subjects on day 90. During SSKI administration, no EG patient had suppressed basal and TRHstimulated TSH concentrations.
In the eight euthyroid EG subjects, serum T4 concentrations did not change during SSKI administration, whereas serum T3 concentrations showed a significant increase, reaching the highest value on day 90 (2.1 + 0.1 nmol/L; P < 0.05, by 1 way ANOVA). However, none of these subjects had serum T3 concentrations above the upper limit of normal.
In the seven AbTPO-positive EG subjects, the antibody levels slightly, but significantly, increased (P < 0.05, by lway ANOVA) during SSKI administration, reaching a peak of 5478 f 2437 U/ml on day 90. Serum TSH-RAb remained undetectable during SSKI administration. Serum AbTPO and TSH-RAb remained undetectable in the control women.
Thyroid status after SSKZ SSKI was discontinued after day 90, and all subjects were reevaluated 60 and 120 days later. Serum TSH was undetectable on day 60 and did not increase after TRH in one EG patient (Table 3 ). The TSH response to TRH was blunted in two others. The two EG women who had elevated basal or TRH-stimulated serum TSH concentrations during SSKI administration had serum basal and TRH-stimulated TSH values similar to those observed before SSKI was administered. The remaining five EG subjects had basal and TRH-stimulated serum TSH concentrations similar to those observed before SSKI administration. The EG subject with undetectable serum TSH and no TSH response to TRH had serum T4 and T3 concentrations above the upper limit of normal (230 and 3.95 nmol/L, respectively; with a blunted TSH response to TRH had serum T4 and T3 concentrations within the normal range. These two subjects did not have any signs or symptoms of hyperthyroidism.
One hundred and twenty days after SSKI was discontinued, a second EG patient had an undetectable serum TSH concentration and no TSH response to TRH and had elevated serum T4 and TX concentrations of 234.3 and 4.3 nmol/L, respectively (Table 3 ). This patient was clinically hyperthyroid and was also treated with MMI. The two EC subjects who had a blunted TSH response to TRH continued to have a reduced TSH response, had serum T4 and TJ concentrations within the normal range, and had no signs or symptoms of hyperthyroidism. Thus, by 120 days after SSKI was discontinued, two patients had developed hyperthyroidism, two patients had a blunted TSH response to TRH but remained euthyroid, and six patients remained euthyroid with normal basal and TRH-stimulated serum TSH values.
The 24-h thyroid lz31 uptakes in the two hyperthyroid patients during MM1 treatment were 37% and 49%, respectively.
Thyroid function tests in the six EG patients who did not develop thyroid dysfunction and in the four control women before, during, and after SSKI administration are reported in Table 4 .
After SSKI was discontinued, serum TSH-RAb remained undetectable in all control and EG subjects, including the two EG patients who developed hyperthyroidism.
Discussion
In previous studies, it has been suggested that iodineinduced hyperthyroidism may occur in subjects with subclinical Graves' disease (1). Subjects residing in an endemic iodine-deficient goiter area with positive circulating longacting thyroid stimulator or long-acting thyroid stimulator protector developed hyperthyroidism during iodine prophylaxis, suggesting that Graves' hyperthyroidism was not pre- EFFECTS   OF IODINE  IN EUTHYROID  GRAVES'  DISEASE  931   TABLE   4 . Serum T,, TB, and basal and TRH-stimulated serum TSH concentrations before, during, and after SSKI administration in six EG subjects who remained euthyroid during and after SSKI administration and in the four control women (C) All values are the mean f SE.
viously present due to inadequate iodine intake (12). Patients with T3 toxicosis due to latent Graves' disease may also develop overt hyperthyroidism after iodine administration (13). Furthermore, it has been suggested that increased dietary iodine intake was associated with an increased recurrence rate of Graves' hyperthyroidism (4,5). In a prospective study, the administration of small quantities of iodine (200 &day) to euthyroid subjects immediately or 6 months after antithyroid drugs were discontinued in patients with Graves' disease induced a small increase in the serum protein-bound iodine concentration and an increased recurrence rate of clinical hyperthyroidism (7). However, in another study, Thalassinos and Fraser (8) reported that the administration of 10 mg iodine daily to euthyroid subjects previously treated with antithyroid drugs for Graves' disease did not increase the recurrence rate of hyperthyroidism. Patients thyroidectomized for Graves' disease who resided in an area with an elevated iodine intake had a higher recurrence rate of hyperthyroidism than patients residing in an area with a low iodine intake (14). Finally, antithyroid drugs were less effective in controlling the hyperthyroidism of patients residing in a region with adequate iodine intake than in patients living in an area of low iodine intake (15).
In the present study, we observed that euthyroid subjects with a previous episode of Graves' hyperthyroidism treated with MM1 did not develop hyperthyroidism during the administration of large amounts of iodine. However, two patients developed hyperthyroidism after SSKI was discontinued. Vagenakis et al. (16) observed that subjects with nontoxic nodular goiter treated with pharmacological amounts of SSKI developed mild hyperthyroidism, which became far worse after iodine was discontinued. Emerson et al. (17) observed that iodine administration to patients with hyperthyroid Graves' disease decreased serum thyroid hormone concentrations, although a rebound increase was observed during the continued administration of iodine. We have previously observed that patients with hyperthyroid Graves' disease had normal serum thyroid hormone concentrations during iodine administration, but that serum thyroid hormone concentrations rapidly rebounded to elevated values after iodine was discontinued (18). In a single patient with iodine-induced hyperthyroidism, further iodine administration resulted in an amelioration of the hyperthyroidism (19). These findings suggest that the effects of iodine on thyroid function in patients with active or potential hyperthyroidism are probably due to at least two mechanisms. First, excess iodine partially decreases thyroid hormone release from the gland, especially in patients with hyperthyroidism (20), thus partially explaining the transient improvement during iodine therapy in hyperthyroid patients. Second, iodine administration may result in continued and even excessive synthesis of thyroid hormones, especially in areas of decreased iodine intake or in thyroids with diffuse or nodular autonomy.
In the two EG patients who developed hyperthyroidism after SSKI was discontinued, serum TSH-RAb were not present before, during, and after iodine administration. This finding does not exclude the diagnosis of recurrent Graves' disease, since it has been reported that not all patients with Graves' disease have TSH-RAb (21). It is unlikely that these two EG patients had autonomous thyroid function before and during SSKI administration, since basal and TRH-stimulated serum TSH concentrations were normal. Others have observed focal inflammatory lesions in the thyroids from patients with iodine-induced hyperthyroidism, suggesting a destructive process with leakage of thyroid hormones into the blood (22). We did not observe any signs or symptoms suggesting subacute thyroiditis in the two EG patients who developed hyperthyroidism after iodine withdrawal. Thus, in the two EG subjects who developed hyperthyroidism after iodine was discontinued, the onset of hyperthyroidism may have been due to increased synthesis of thyroid hormone and partial inhibition of hormone release during iodine administration, with a subsequent release of stored hormone after iodine withdrawal. It is also possible that these two patients might have developed spontaneous recurrent hyperthyroidism regardless of iodine administration.
A positive I-ClO, discharge test is a marker of an intrathyroid iodine organification defect and subsequent decreased hormone synthesis (23, 24) , but may also be due to an increased intrathyroid iodide content due to enhanced trap-ping of iodide, since a large number of patients newly diagnosed with Graves' hyperthyroidism have a positive iodine discharge test (our personal observation). In the present study, only 4 of 10 euthyroid women previously treated with MM1 for hyperthyroid Graves' disease had a positive I-C104 discharge test, and only 1 developed iodine-induced subclinical hypothyroidism. The other patient who developed iodine-induced subclinical hypothyroidism had a negative I-Clod discharge test. This is in contrast to the high prevalence of iodine-induced hypothyroidism and positive I-ClO, discharge tests in euthyroid patients previously treated for active Graves' disease with definitive therapy, such as radioactive iodine and subtotal thyroidectomy (6); in euthyroid patients with a history of inflammatory thyroid disease, such as subacute (De Quervain) (25), Hashimoto's (26) , and postpartum thyroiditis (9); in some patients with a previous history of amiodarone-induced thyrotoxicosis (27) ; and in euthyroid patients with a previous lobectomy for uninodular goiter (28) .
In conclusion, it is probably advisable to avoid administering pharmacological quantities of iodine to euthyroid patients with a history of antithyroid drug therapy for hyperthyroid Graves' disease, since it is not possible to predict which patient will develop iodine induced hyper-or hypothyroidism.
